Literature DB >> 22514338

Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein.

Michele Celestino1, Arianna Calistri, Claudia Del Vecchio, Cristiano Salata, Flavia Chiuppesi, Mauro Pistello, Alessandra Borsetti, Giorgio Palù, Cristina Parolin.   

Abstract

Tetherin (BST2) is the host cell factor that blocks the particle release of some enveloped viruses. Two putative feline tetherin proteins differing at the level of the N-terminal coding region have recently been described and tested for their antiviral activity. By cloning and comparing the two reported feline tetherins (called here cBST2(504) and cBST2*) and generating specific derivative mutants, this study provides evidence that feline tetherin has a shorter intracytoplasmic domain than those of other known homologues. The minimal tetherin promoter was identified and assayed for its ability to drive tetherin expression in an alpha interferon-inducible manner. We also demonstrated that cBST2(504) is able to dimerize, is localized at the cellular membrane, and impairs human immunodeficiency virus type 1 (HIV-1) particle release, regardless of the presence of the Vpu antagonist accessory protein. While cBST2(504) failed to restrict wild-type feline immunodeficiency virus (FIV) egress, FIV mutants, bearing a frameshift at the level of the envelope-encoding region, were potently blocked. The transient expression of the FIV envelope glycoprotein was able to rescue mutant particle release from feline tetherin-positive cells but did not antagonize human BST2 activity. Moreover, cBST2(504) was capable of specifically immunoprecipitating the FIV envelope glycoprotein. Finally, cBST2(504) also exerted its function on HIV-2 ROD10 and on the simian immunodeficiency virus SIVmac239. Taken together, these results show that feline tetherin does indeed have a short N-terminal region and that the FIV envelope glycoprotein is the predominant factor counteracting tetherin restriction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22514338      PMCID: PMC3393548          DOI: 10.1128/JVI.07037-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.

Authors:  D A Regier; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

Review 2.  FIV infection of the domestic cat: an animal model for AIDS.

Authors:  B J Willett; J N Flynn; M J Hosie
Journal:  Immunol Today       Date:  1997-04

Review 3.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

4.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

5.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.

Authors:  Christine Goffinet; Ina Allespach; Stefanie Homann; Hanna-Mari Tervo; Anja Habermann; Daniel Rupp; Lena Oberbremer; Christian Kern; Nadine Tibroni; Sonja Welsch; Jacomine Krijnse-Locker; George Banting; Hans-Georg Kräusslich; Oliver T Fackler; Oliver T Keppler
Journal:  Cell Host Microbe       Date:  2009-03-19       Impact factor: 21.023

6.  HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin.

Authors:  Naoko Masuyama; Toshio Kuronita; Rika Tanaka; Tomonori Muto; Yuko Hirota; Azusa Takigawa; Hideaki Fujita; Yoshinori Aso; Jun Amano; Yoshitaka Tanaka
Journal:  J Biol Chem       Date:  2009-04-08       Impact factor: 5.157

7.  Identification of a feline immunodeficiency virus gene which is essential for cell-free virus infectivity.

Authors:  K Tomonaga; J Norimine; Y S Shin; M Fukasawa; T Miyazawa; A Adachi; T Toyosaki; Y Kawaguchi; C Kai; T Mikami
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

8.  Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.

Authors:  Daniel Sauter; Michael Schindler; Anke Specht; Wilmina N Landford; Jan Münch; Kyeong-Ae Kim; Jörg Votteler; Ulrich Schubert; Frederic Bibollet-Ruche; Brandon F Keele; Jun Takehisa; Yudelca Ogando; Christina Ochsenbauer; John C Kappes; Ahidjo Ayouba; Martine Peeters; Gerald H Learn; George Shaw; Paul M Sharp; Paul Bieniasz; Beatrice H Hahn; Theodora Hatziioannou; Frank Kirchhoff
Journal:  Cell Host Microbe       Date:  2009-11-19       Impact factor: 21.023

9.  Cloning and characterization of the antiviral activity of feline Tetherin/BST-2.

Authors:  Aiko Fukuma; Masumi Abe; Yuko Morikawa; Takayuki Miyazawa; Jiro Yasuda
Journal:  PLoS One       Date:  2011-03-29       Impact factor: 3.240

10.  Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.

Authors:  Sara L Sawyer; Michael Emerman; Harmit S Malik
Journal:  PLoS Biol       Date:  2004-07-20       Impact factor: 8.029

View more
  25 in total

1.  ATP1B3 Protein Modulates the Restriction of HIV-1 Production and Nuclear Factor κ Light Chain Enhancer of Activated B Cells (NF-κB) Activation by BST-2.

Authors:  Hironori Nishitsuji; Ryuichi Sugiyama; Makoto Abe; Hiroshi Takaku
Journal:  J Biol Chem       Date:  2015-12-22       Impact factor: 5.157

2.  HIV-1 Nefs Are Cargo-Sensitive AP-1 Trimerization Switches in Tetherin Downregulation.

Authors:  Kyle L Morris; Cosmo Z Buffalo; Christina M Stürzel; Elena Heusinger; Frank Kirchhoff; Xuefeng Ren; James H Hurley
Journal:  Cell       Date:  2018-07-26       Impact factor: 41.582

3.  Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation.

Authors:  James H Morrison; Rebekah B Guevara; Adriana C Marcano; Dyana T Saenz; Hind J Fadel; Daniel K Rogstad; Eric M Poeschla
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

Review 4.  The cytoplasmic tail of retroviral envelope glycoproteins.

Authors:  Philip R Tedbury; Eric O Freed
Journal:  Prog Mol Biol Transl Sci       Date:  2014-12-01       Impact factor: 3.622

Review 5.  Tetherin/BST-2: Restriction Factor or Immunomodulator?

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; Mario L Santiago
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

6.  Stimulation of NF-κB activity by the HIV restriction factor BST2.

Authors:  Andrey Tokarev; Marissa Suarez; Wilson Kwan; Kathleen Fitzpatrick; Rajendra Singh; John Guatelli
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

Review 7.  Cell-to-cell transmission of viruses.

Authors:  Peng Zhong; Luis M Agosto; James B Munro; Walther Mothes
Journal:  Curr Opin Virol       Date:  2012-12-05       Impact factor: 7.090

8.  Differential type 1 interferon-regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence.

Authors:  Maria J Polyak; Pornpun Vivithanaporn; Ferdinand G Maingat; John G Walsh; William Branton; Eric A Cohen; Rick Meeker; Christopher Power
Journal:  FASEB J       Date:  2013-04-22       Impact factor: 5.191

9.  The HERV-K human endogenous retrovirus envelope protein antagonizes Tetherin antiviral activity.

Authors:  Cécile Lemaître; Francis Harper; Gérard Pierron; Thierry Heidmann; Marie Dewannieux
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

10.  Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein.

Authors:  Xin Yin; Zhe Hu; Qinyong Gu; Xingliang Wu; Yong-Hui Zheng; Ping Wei; Xiaojun Wang
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.